Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Research & Development (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Research & Development for 8 consecutive years, with $14.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 43.49% to $14.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $86.3 million, a 74.49% increase, with the full-year FY2024 number at $51.0 million, up 4.29% from a year prior.
  • Research & Development was $14.3 million for Q3 2025 at Whitehawk Therapeutics, down from $48.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $48.8 million in Q2 2025 to a low of $3.0 million in Q2 2021.
  • A 5-year average of $12.1 million and a median of $10.5 million in 2023 define the central range for Research & Development.
  • Biggest YoY gain for Research & Development was 272.79% in 2025; the steepest drop was 35.35% in 2025.
  • Whitehawk Therapeutics' Research & Development stood at $7.2 million in 2021, then increased by 29.65% to $9.4 million in 2022, then soared by 36.26% to $12.8 million in 2023, then rose by 12.37% to $14.3 million in 2024, then dropped by 0.01% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Research & Development are $14.3 million (Q3 2025), $48.8 million (Q2 2025), and $8.8 million (Q1 2025).